Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
01:06am, Thursday, 19'th Sep 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluz
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
01:00am, Thursday, 19'th Sep 2024
Basel, 19 September - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results of the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral, showing a reductio
"Everyone Should Applaud" Powell for 50bps: Cullen Roche
04:19pm, Wednesday, 18'th Sep 2024
Cullen Roche says the Fed is "thinking in a proactive sense" after announcing a 50BPS rate cut. He points to Fed Chair Jerome Powell's transparency to help "reduce the risk of a hard landing.
Healthy Returns: How competitive can Roche be in the weight loss drug market?
03:00pm, Tuesday, 17'th Sep 2024
Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 17'th Sep 2024
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Roche Holding AG (RHHBY) and AbbVie (ABBV). But which of these two stocks is more attractive to value investors?
Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq)
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
01:56pm, Friday, 13'th Sep 2024
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO , Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NAS
Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe
09:26am, Friday, 13'th Sep 2024
RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
03:51am, Friday, 13'th Sep 2024
Roche, a big pharmaceutical company, recently shared details from an early-stage trial with its oral anti-obesity candidate. Roche's oral anti-obesity candidate outperformed a similar candidate from V
FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
01:00am, Friday, 13'th Sep 2024
Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), t
US FDA approves injectable version of Roche's multiple sclerosis therapy
08:34pm, Thursday, 12'th Sep 2024
The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple sclerosis.
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
08:00pm, Thursday, 12'th Sep 2024
FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy SAN DIEGO , Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
07:32pm, Thursday, 12'th Sep 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr
Roche's Manu Chakravarthy talks weight loss drug trial results
06:49pm, Thursday, 12'th Sep 2024
Manu Chakravarthy, Roche, joins 'Fast Money' to talk its weight loss drug trial results.
